Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone): evaluation report

Contents:

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Janssen

03 Consultee comments on the ACD - Prostate Cancer UK

04 Consultee comments on the ACD - TACKLE

05 Consultee comments on the ACD - BAUN

06 Consultee comments on the ACD - BUG

07 Consultee comments on the ACD - NCRI-RCP-RCR-ACP-JCCO

08 Commentator comments on the ACD - DH

09 Commentator comments on the ACD - Sanofi

10 Commentator comments on the ACD - ICR

11 Public comments on the ACD received via the NICE website

12 Evidence Review Group Addendum

13 Additional Document from the manufacturer Janssen

 

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report. It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 14 August 2014